U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4S
Molecular Weight 96.063
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -2

SHOW SMILES / InChI
Structure of SULFATE ION

SMILES

[O-]S([O-])(=O)=O

InChI

InChIKey=QAOWNCQODCNURD-UHFFFAOYSA-L
InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)/p-2

HIDE SMILES / InChI
Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

SULFATE (as sodium sulfate, potassium sulfate, and magnesium sulfate) is a component of SUPREP Bowel Prep Kit. It is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. Sulfate salts provide sulfate anions, which are poorly absorbed. The osmotic effect of unabsorbed sulfate anions and the associated cations causes water to be retained within the gastrointestinal tract. SUPREP Bowel Prep Kit, when ingested with a large volume of water, produces copious watery diarrhea.

Approval Year

1921
1468
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
SUPREP Bowel Prep Kit

Approved Use

SUPREP Bowel Prep Kit is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

Launch Date

2010
PubMed

PubMed

TitleDatePubMed
Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase.
2014-04
Evaluation of formocresol versus ferric sulphate primary molar pulpotomy: a systematic review and meta-analysis.
2007-10
Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.
2007-07-18
Heparan sulphate proteoglycans fine-tune mammalian physiology.
2007-04-26
Overcoming chondroitin sulphate proteoglycan inhibition of axon growth in the injured brain: lessons from chondroitinase ABC.
2007
[Therapy of osteoarthritis crystalline glucosamine sulphate/a review of the clinical effcacy].
2007
Chondroitin sulphate: antioxidant properties and beneficial effects.
2006-12
Dietary acidification enhances phosphorus digestibility but decreases H+/K+-ATPase expression in rainbow trout.
2006-10
The role of heparan sulphate in inflammation.
2006-09
Interferon and heparan sulphate.
2006-06
Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily.
2006-06
Heparan sulphate requirement in platelet-derived growth factor B-mediated pericyte recruitment.
2006-06
The role of heparan sulphate proteoglycans in angiogenesis.
2006-06
Insights into the role of heparan sulphate in fibroblast growth factor signalling.
2006-06
Multiprotein signalling complexes: regional assembly on heparan sulphate.
2006-06
Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors.
2006-06
Heparan sulphate proteoglycans and viral vectors : ally or foe?
2006-02
[Magnesium sulphate for the management of preeclampsia].
2006-01
Heparan sulphate proteoglycans: the sweet side of development.
2005-07
A review of the role for magnesium sulphate in preterm labour.
2005-03
Evidence and practice: the magnesium sulphate story.
2005-02
A meta-analysis on intravenous magnesium sulphate for treating acute asthma.
2005-01
Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery.
2005
Epidemiology of 377 patients with chemical burns in Guangdong province.
2004-09
Characterization of the Herpesvirus saimiri Orf51 protein.
2004-08-15
Molecular recognition by LARGE is essential for expression of functional dystroglycan.
2004-06-25
[The extracellular matrix of the central nervous system: chondroitin sulphate type proteoglycans and neural repair].
2004-05-21
The SLC13 gene family of sodium sulphate/carboxylate cotransporters.
2004-02
Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?
2004-01
Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies.
2003-10
Dermatan sulphate as an antithrombotic drug.
2003-09-19
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders.
2003-08
Magnesium sulphate versus phenytoin for eclampsia.
2003
Magnesium sulphate versus diazepam for eclampsia.
2003
Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.
2003
Structure-activity relationship of heparan sulphate.
1997-11
Heparan sulphate proteoglycan and wound healing in skin.
1997-11
Heparan sulphate.
1997-05
Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease.
1996-09
The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide.
1996-06
The role of stromal cell heparan sulphate in regulating haemopoiesis.
1996-05
Two selectins converge on sulphate. Leukocyte adhesion.
1996-03-01
Renal and small intestinal sodium-dependent symporters of phosphate and sulphate.
1994-11
Dextran sulphate induces a PKC and actin independent internalisation of CD4.
1994-09
Keratan sulphate--a 'reserve' polysaccharide?
1994-04
Death by tanning--a case of fatal basic chromium sulphate poisoning.
1994
Heparan sulphate in the binding and activation of basic fibroblast growth factor.
1992-12
Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme.
1992-04
Sodium dodecyl sulphate electrophoresis of urinary proteins.
1991-09-13
Management of autonomic dysfunction in severe tetanus: the use of magnesium sulphate and clonidine.
1990
Patents

Patents

03931143
18
03931217
11
03931218
8
03931239
40
03931412
38
03932479
113
03932483
75
03932505
9
03932630
8
03939185
8
03940407
9
03940411
10
03943151
8
03943154
10
03946008
9
03947582
13
03966830
12
03983253
8
03992189
9
04001300
8
04013695
8
04016182
8
04028419
8
04036979
11
04049659
9
04052511
9
04055602
8
04061771
13
04066543
8
04073798
9
04078006
10
04086278
8
04086338
9
04105776
11
04124601
8
04128653
8
04154840
20
04154937
8
04156670
9
04160657
8
04164543
15
04171447
8
04190433
8
04191830
9
04205178
8
04229207
8
04242265
9
04273704
8
04278808
8
04324729
8
04337197
8
04340415
8
04340747
8
04342737
8
04350633
10
04351846
8
04355105
8
04395414
9
04396772
8
04401808
9
04453013
9
04454291
8
04454292
8
04461896
19
04477369
8
04533660
38
04536402
8
04549019
11
04565882
9
04611002
8
04613463
36
04621078
8
04657700
8
04690936
11
04692458
9
04711895
9
04734420
74
04736057
9
04745124
9
04751018
9
04760161
9
04764512
8
04778790
8
04788010
8
04831153
8
04889859
10
04894458
13
04931568
8
04954278
8
04954328
9
05112863
8
05232624
8
05401621
8
06071927
11
06110491
8
06528526
8
07932007
8
07932354
8

Sample Use Guides

In Vivo Use Guide
Split-Dose (2-Day) Regimen: The evening before colonoscopy: dilute one bottle with water to a total volume of 16 oz. (up to the fill line) and drink the entire amount. Drink 32 ounces of water over the next hour. Next morning: repeat both steps using the second bottle. Complete preparation at least 2 hours before colonoscopy or as directed by a physician.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:20:26 GMT 2025
Edited
by admin
on Mon Mar 31 18:20:26 GMT 2025
Record UNII
7IS9N8KPMG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFATE
VANDF  
Preferred Name English
SULFATE ION
Common Name English
SULFATE(2-)
Common Name English
SULPHATE
Systematic Name English
SULPHATE ION
Common Name English
SULPHATE(2-)
Common Name English
SULFATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C597
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 39576-4
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 20973-4
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 2975-1
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 9486-2
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 12920-5
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 20974-2
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
DSLD 143 (Number of products:47)
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 26889-6
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 26888-8
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 43754-1
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
NDF-RT N0000175811
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
LOINC 17666-9
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C76207
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID3042425
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
PUBCHEM
1117
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
SMS_ID
100000089045
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
CHEBI
16189
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
RXCUI
1426598
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY RxNorm
CAS
14808-79-8
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
FDA UNII
7IS9N8KPMG
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
EVMPD
SUB22774
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
DAILYMED
7IS9N8KPMG
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
DRUG BANK
DB14546
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
WIKIPEDIA
SULFATE
Created by admin on Mon Mar 31 18:20:26 GMT 2025 , Edited by admin on Mon Mar 31 18:20:26 GMT 2025
PRIMARY
Related Record Type Details
Structure of Salicylic acid
PARENT -> IMPURITY
EP
Structure of LYSINE ACETATE
PARENT -> IMPURITY
EP
Structure of METHIONINE
PARENT -> IMPURITY
EP
Structure of TRYPTOPHAN
PARENT -> IMPURITY
EP
Structure of LYSINE HYDROCHLORIDE
PARENT -> IMPURITY
EP
Related Record Type Details
Structure of SULFATE ION
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966